Technical Description
This invention describes a vorapaxar which acts as a Leishmania donovani Citrate Synthase 5 (LdCS) inhibitor, offering oral treatment potential against Leishmania donovani strain Ag83.
Problems Addressed
- Drug Resistance Issue
- High Treatment Cost
- Severe Side Effects
- Inefficient Drug Delivery
- Limited Oral Therapeutics
- Targets Parasite Life Cycle
Tech Features
- Enhanced Drug Targeting
- Efficient LdCS Inhibition
- Optimized Oral Formulation
- Potent Against Drug-Resistant Strains
- Advanced Parasite Stage Targeting
Target Audience
- Solar Power Plant Operator Sectors
- Photovoltaic (PV) Module Manufacturing Industry
- Academic & Research Institutions
- Energy and Utility Industries
- Semiconductor & Electronics Manufacturing Industries
Tech ID: P27-1389 TRL 3 Patent Status: Granted Available For Exclusive and Non-exclusive License
